Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-5. (Cancelled).

6. (New) An adhesive preparation for percutaneous absorption consisting essentially of:

a base for the adhesive preparation which contains a styrene-isoprene-styrene block copolymer;

an amount of norethisterone dissolved in the base preparation without crystallization in the absence of hexylene glycol;

estradiol in an amount not more than 2 % by weight based on the whole base;

a softener selected from liquid paraffin, polybutene, castor oil, cottonseed oil, palm oil, coconut oil, and processed oil; and

an adhesive resin selected from alicyclic saturated hydrocarbon resins, rosin ester, hydrogen alicyclic hydrocarbon, terpene-based hydrogenated resin, and hydrogenated rosin ester.

7. (New) The adhesive preparation for percutaneous absorption according to claim 6, wherein norethisterone is dissolved in the amount showing the releasing rate in water being not less than 30% after 25 hours determined by the drug releasing test according to the cylinder method described in the USP Dug release Test under the following conditions:

Test solution	900 ml water;
Temperature of test solution	32.0 ± 0.5°C;
Distance from the lowest end of cylinder to the basal inner plane of vessel	25 ± 2 mm; and
Revolution of cylinder	50 rpm.

8. (New) An adhesive preparation for percutaneous absorption consisting essentially of:

a base for the adhesive preparation which contains a styrene-isoprene-styrene block copolymer;

an amount of norethisterone dissolved in the base preparation without crystallization in the absence of hexylene glycol;

estradiol in an amount not more than 2 % by weight based on the whole base;

a softener selected from liquid paraffin, polybutene, castor oil, cottonseed oil, palm oil, coconut oil, and processed oil;

an adhesive resin selected from alicyclic saturated hydrocarbon resins, rosin ester, hydrogen alicyclic hydrocarbon, terpene-based hydrogenated resin, and hydrogenated rosin ester; and

a polyisobutylene solubilizing agent.

9. (New) The adhesive preparation for percutaneous absorption according to claim 8, wherein norethisterone is dissolved in the amount showing the releasing rate in water being not less than 30% after 25 hours determined by the drug releasing test according to the cylinder method described in the USP Dug release Test under the following conditions:

Test solution	900 ml water;
Temperature of test solution	32.0 ± 0.5°C;
Distance from the lowest end of cylinder to the basal inner plane of vessel	25 ± 2 mm; and
Revolution of cylinder	50 rpm.

10. (New) The adhesive preparation for percutaneous absorption according to any of claims 6 – 9, wherein an amount of norethisterone to be dissolved is in the amount not more than 2 % by weight based on the whole base.

11. (New) The adhesive preparation for percutaneous absorption according to any of claims 6 - 9, wherein the adhesive preparation containing a styrene-isoprene-styrene block

copolymer comprises 10 – 30 % by weight of a styrene-isoprene-styrene block copolymer, 10 – 60 % by weight of a softener and 20 – 60 % by weight of an adhesive resin based on the whole base.